Reportlinker Adds Ion Channel Modulator Pipelines: Targets and Agents in Development [More]

Sanofi-aventis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone - 400mg Tablets). [More]

Sanofi-aventis Canada announced today that Multaq (dronedarone, 400 mg tablets) has received Health Canada approval for the treatment of patients with a history of, or current atrial fibrillation to reduce their risk of cardiovascular hospitalization due to this condition. [More]

Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL. [More]

The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat. [More]

Sanofi-aventis has announced that the Cardiovascular and Renal Drugs Advisory Committee voted 10 to 3 in favor of the approval of Multaq by the U.S. Food and Drug Administration (FDA) to treat patients with non-permanent atrial fibrillation (AF). [More]

Results from the ATHENA trial, reported in the 12th February issue of the New England Journal of Medicine , suggest that the (as yet unlicensed) antiarrhythmic drug dronedarone can reduce the incidence of cardiovascular-related hospitalisation or death in patients with atrial fibrillation. [More]

The results of a post-hoc analysis of the data from the ATHENA study were presented today at the clinical trial update session of the European Society of Cardiology congress 2008, in Munich, Germany. [More]

New anti-arrhythmic agent, dronedarone, is highly effective in the prevention of atrial fibrillation or atrial flutter recurrence, serious disorders of cardiac rhythm, and is well-tolerated by patients. [More]